Arrowhead FY2024 net loss widens to $599.5 million on revenue of $3.6 million
Arrowhead Pharmaceuticals reported a fiscal 2024 net loss attributable to the company of $599.5 million, or $5.00 per diluted share, for the year ended September 30, 2024, compared with a loss of $205.3 million, or $1.92 per share, a year earlier. Revenue fell to $3.6 million from $240.7 million, while research and development expense rose to $505.9 million from $353.2 million. The company said its recent Sarepta licensing deal and Sixth Street credit facility, both announced in the filing period, extend its cash runway into 2028.
Key points
- Revenue was $3.6 million in fiscal 2024 versus $240.7 million in fiscal 2023.
- Diluted net loss per share was $5.00 versus $1.92 a year earlier.
- Research and development expense was $505.9 million versus $353.2 million.
- Sarepta agreement provides $825 million upon closing, including a $325 million equity investment; Sixth Street facility is $500 million, with $400 million funded at close.
The filing
Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 26, 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.